Good Practices for the Laboratory Performance Testing of Aqueous Oral Inhaled Products (OIPs): an Assessment from the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS)
- PMID: 36869256
- DOI: 10.1208/s12249-023-02528-5
Good Practices for the Laboratory Performance Testing of Aqueous Oral Inhaled Products (OIPs): an Assessment from the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS)
Abstract
Multiple sources must be consulted to determine the most appropriate procedures for the laboratory-based performance evaluation of aqueous oral inhaled products (OIPs) for the primary measures, dose uniformity/delivery, and aerodynamic particle (droplet) size distribution (APSD). These sources have been developed at different times, mainly in Europe and North America, during the past 25 years by diverse organizations, including pharmacopeial chapter/monograph development committees, regulatory agencies, and national and international standards bodies. As a result, there is a lack of consistency across all the recommendations, with the potential to cause confusion to those developing performance test methods. We have reviewed key methodological aspects of source guidance documents identified by a survey of the pertinent literature and evaluated the underlying evidence supporting their recommendations for the evaluation of these performance measures. We have also subsequently developed a consistent series of solutions to guide those faced with the various associated challenges when developing OIP performance testing methods for oral aqueous inhaled products.
Keywords: cascade impactor; droplet sizing; laser diffractometry; nebulizer; soft mist inhaler.
© 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Similar articles
-
Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.AAPS PharmSciTech. 2019 May 30;20(5):206. doi: 10.1208/s12249-019-1416-x. AAPS PharmSciTech. 2019. PMID: 31147791
-
Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).AAPS PharmSciTech. 2020 Aug 21;21(7):239. doi: 10.1208/s12249-020-01720-1. AAPS PharmSciTech. 2020. PMID: 32827121 Review.
-
Laboratory Performance Testing of Aqueous Nasal Inhalation Products for Droplet/Particle Size Distribution: an Assessment from the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS).AAPS PharmSciTech. 2023 Oct 10;24(7):208. doi: 10.1208/s12249-023-02665-x. AAPS PharmSciTech. 2023. PMID: 37817001
-
Measurement of Aerodynamic Particle Size Distribution of Orally Inhaled Products by Cascade Impactor: How to Let the Product Specification Drive the Quality Requirements of the Cascade Impactor.AAPS PharmSciTech. 2019 Jan 8;20(2):57. doi: 10.1208/s12249-018-1276-9. AAPS PharmSciTech. 2019. PMID: 30623259 Review.
-
Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol.AAPS PharmSciTech. 2017 Nov;18(8):3296-3306. doi: 10.1208/s12249-017-0814-1. Epub 2017 Jun 6. AAPS PharmSciTech. 2017. PMID: 28589305
References
-
- VanOort M. In vitro testing of dry powder inhalers. Aerosol Sci Technol. 1995;22(4):364–73. - DOI
-
- Mitchell JP, Stein SW, Doub W, Goodey AP, Christopher JD, Patel RB, et al. Determination of passive dry powder inhaler aerodynamic particle size distribution by multi-stage cascade impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) recommendations to support both product quality control and clinical programs. AAPS PharmSciTech. 2019;20 article 206.
-
- United States Pharmacopeial Convention. United States Pharmacopeia. Chapter <601>: Inhalation and nasal drug products: aerosols, sprays, and powders – performance quality tests. Rockwell, MD, USA. https://uspnf.com/uspnf/ (visited April 18, 2022).
-
- European Directorate for the Quality of Medicines and Healthcare (EDQM). Strasbourg, France. Monograph 2.9.18: preparations for inhalation: aerodynamic assessment of fine particles. https://edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition (visited April 18, 2022).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous